Soligenix (SNGX) Competitors $1.75 +0.10 (+5.82%) As of 01:09 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SNGX vs. DARE, ENLV, CVKD, PASG, LPTX, PMN, LNAI, CASI, MIRA, and TAOXShould you be buying Soligenix stock or one of its competitors? The main competitors of Soligenix include Dare Bioscience (DARE), Enlivex Therapeutics (ENLV), Cadrenal Therapeutics (CVKD), Passage Bio (PASG), Leap Therapeutics (LPTX), Promis Neurosciences (PMN), Lunai Bioworks (LNAI), CASI Pharmaceuticals (CASI), MIRA Pharmaceuticals (MIRA), and Synaptogenix (TAOX). These companies are all part of the "pharmaceutical products" industry. Soligenix vs. Its Competitors Dare Bioscience Enlivex Therapeutics Cadrenal Therapeutics Passage Bio Leap Therapeutics Promis Neurosciences Lunai Bioworks CASI Pharmaceuticals MIRA Pharmaceuticals Synaptogenix Dare Bioscience (NASDAQ:DARE) and Soligenix (NASDAQ:SNGX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, media sentiment, dividends, earnings, risk, analyst recommendations, profitability and valuation. Which has more risk & volatility, DARE or SNGX? Dare Bioscience has a beta of 1.14, suggesting that its share price is 14% more volatile than the S&P 500. Comparatively, Soligenix has a beta of 1.95, suggesting that its share price is 95% more volatile than the S&P 500. Do analysts rate DARE or SNGX? Dare Bioscience presently has a consensus target price of $10.00, indicating a potential upside of 389.00%. Soligenix has a consensus target price of $6.00, indicating a potential upside of 243.64%. Given Dare Bioscience's stronger consensus rating and higher probable upside, equities analysts plainly believe Dare Bioscience is more favorable than Soligenix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dare Bioscience 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33Soligenix 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do institutionals and insiders have more ownership in DARE or SNGX? 6.7% of Dare Bioscience shares are held by institutional investors. Comparatively, 3.6% of Soligenix shares are held by institutional investors. 4.8% of Dare Bioscience shares are held by company insiders. Comparatively, 3.1% of Soligenix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the media favor DARE or SNGX? In the previous week, Soligenix had 1 more articles in the media than Dare Bioscience. MarketBeat recorded 1 mentions for Soligenix and 0 mentions for Dare Bioscience. Dare Bioscience's average media sentiment score of 1.73 beat Soligenix's score of 0.00 indicating that Dare Bioscience is being referred to more favorably in the media. Company Overall Sentiment Dare Bioscience Very Positive Soligenix Neutral Is DARE or SNGX more profitable? Dare Bioscience's return on equity of 0.00% beat Soligenix's return on equity.Company Net Margins Return on Equity Return on Assets Dare BioscienceN/A N/A -103.70% Soligenix N/A -274.76%-129.20% Which has stronger earnings and valuation, DARE or SNGX? Dare Bioscience has higher earnings, but lower revenue than Soligenix. Dare Bioscience is trading at a lower price-to-earnings ratio than Soligenix, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDare Bioscience$10K2,756.66-$4.05M-$2.14-0.96Soligenix$120K62.42-$8.27M-$3.80-0.46 SummaryDare Bioscience beats Soligenix on 11 of the 15 factors compared between the two stocks. Get Soligenix News Delivered to You Automatically Sign up to receive the latest news and ratings for SNGX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SNGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNGX vs. The Competition Export to ExcelMetricSoligenixMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.53M$3.47B$6.17B$10.68BDividend YieldN/A2.27%5.72%4.83%P/E Ratio-0.4623.4029.4727.34Price / Sales62.42479.21587.77132.79Price / CashN/A45.2825.8230.35Price / Book1.0610.5212.446.68Net Income-$8.27M-$52.71M$3.32B$276.46M7 Day Performance1.51%4.72%2.15%0.77%1 Month Performance-35.09%15.59%8.41%3.73%1 Year Performance-54.83%13.83%61.67%36.59% Soligenix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNGXSoligenix2.44 of 5 stars$1.75+5.8%$6.00+243.6%-57.3%$7.53M$120K-0.4620DAREDare Bioscience2.536 of 5 stars$2.12flat$10.00+371.7%-45.6%$28.58M$10K-0.9930Positive NewsENLVEnlivex Therapeutics2.6969 of 5 stars$1.10-4.3%$10.00+809.1%-30.3%$27.94MN/A-1.9070Gap UpCVKDCadrenal Therapeutics2.9095 of 5 stars$13.99+2.7%$32.00+128.7%-21.0%$27.88MN/A-1.584PASGPassage Bio3.0727 of 5 stars$8.69+2.6%$75.67+770.7%-30.4%$26.93MN/A-0.48130News CoverageLPTXLeap Therapeutics2.8214 of 5 stars$0.60-5.5%$3.38+459.6%-79.4%$26.46MN/A-0.3840News CoveragePositive NewsAnalyst DowngradeShort Interest ↓Gap UpPMNPromis Neurosciences3.6175 of 5 stars$0.48-2.0%$4.33+802.8%-55.8%$26.37MN/A-2.295Positive NewsShort Interest ↓LNAILunai BioworksN/A$1.16+2.7%N/AN/A$26.19MN/A-0.1520Gap UpCASICASI Pharmaceuticals3.5751 of 5 stars$1.89-4.5%$4.00+111.6%-68.8%$24.35M$28.54M-0.65180MIRAMIRA Pharmaceuticals0.3774 of 5 stars$1.29+2.0%N/A+47.3%$24.03MN/A-2.622Gap DownTAOXSynaptogenix0.0678 of 5 stars$9.54+38.5%N/AN/A$24.03MN/A-0.474News CoverageGap UpHigh Trading Volume Related Companies and Tools Related Companies Dare Bioscience Competitors Enlivex Therapeutics Competitors Cadrenal Therapeutics Competitors Passage Bio Competitors Leap Therapeutics Competitors Promis Neurosciences Competitors Lunai Bioworks Competitors CASI Pharmaceuticals Competitors MIRA Pharmaceuticals Competitors Synaptogenix Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNGX) was last updated on 10/20/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored"I'm risking my reputation on this"The Fed rate cut truth they don't want you to know The Fed's 25 basis point cut isn't just monetary policy…...Crypto 101 Media | SponsoredAI's Next Magnificent SevenThe original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhat Wall Street Won’t Say Out LoudDiscover the 7 key indicators before everyone else doesAmerican Alternative | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredGOLD ALERTGold has shattered records, soaring past $3,800 an ounce... But Stansberry Senior Partner Dr. David "Doc" E...Stansberry Research | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Soligenix Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Soligenix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
